These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 3692271)

  • 1. Conditioning the placebo response in the rotational model of Parkinson's disease.
    Burunat E; Diaz Palarea MD; Castro R; Rodriguez M
    Funct Neurol; 1987; 2(3):263-9. PubMed ID: 3692271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ
    Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism.
    Senthilkumar KS; Saravanan KS; Chandra G; Sindhu KM; Jayakrishnan A; Mohanakumar KP
    Behav Brain Res; 2007 Nov; 184(1):11-8. PubMed ID: 17765334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
    Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
    Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHNO, a novel dopamine agonist, in animal models of parkinsonism.
    Koller W; Herbster G; Gordon J
    Mov Disord; 1987; 2(3):193-9. PubMed ID: 2904649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
    Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS
    Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
    Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
    Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditioning of the early behavioral response to apomorphine in the rotational model of Parkinson's disease.
    Burunat E; Castro R; Díaz-Palarea MD; Rodríguez M
    Eur J Pharmacol; 1988 Jan; 145(3):323-7. PubMed ID: 3127225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression.
    Duty S; Brotchie JM
    Exp Neurol; 1997 Apr; 144(2):423-32. PubMed ID: 9168843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis.
    Metz GA; Tse A; Ballermann M; Smith LK; Fouad K
    Eur J Neurosci; 2005 Aug; 22(3):735-44. PubMed ID: 16101755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Behavioral evaluation of the unilateral lesion model in rats using 6-hydroxydopamine. Correlation between the rotations induced by D-amphetamine, apomorphine and the manual dexterity test].
    Pavón N; Vidal L; Alvarez P; Blanco L; Torres A; Rodríguez A; Macías R
    Rev Neurol; 1998 Jun; 26(154):915-8. PubMed ID: 9658459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditioned response to apomorphine in nigro-striatal system-lesioned rats: the origin of undrugged rotational response.
    Burunat E; Castro R; Diaz-Palarea MD; Rodriguez M
    Life Sci; 1987 Oct; 41(15):1861-6. PubMed ID: 3657388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One trial conditioning with apomorphine is blocked by cycloheximide.
    Silverman PB; Baruch NP; Schultz KA
    Pharmacol Biochem Behav; 1989 Nov; 34(3):663-4. PubMed ID: 2623022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
    Sharma R; McMillan CR; Tenn CC; Niles LP
    Brain Res; 2006 Jan; 1068(1):230-6. PubMed ID: 16375867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.